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Introduction
Epithelial-Mesenchymal Transition (EMT) is a biological process utilized by epithelial
cells to transform into motile mesenchymal cells, initiating metastasis in cancer. EMT is also
utilized during development and wound healing [10]. This process allows for cancerous cells to
detach themselves from their primary tumor and invade normal tissue in preferred organ sites,
forming secondary tumors called metastases. Metastasis is very important in the progression of
cancer in patients as it the process responsible for the mortality of patients through the collection
of metastases that effect vital organs like the brain, lung, or immune system. The most common
metastases for malignant breast tumors are the brain, lungs, lymph nodes, liver, and bone [1]. As
metastasis increases the mortality rate of patients, it is vital to understand then how this process
is initiated by EMT. EMT occurs due to epithelial cells losing their cell-cell adhesion and
polarity. This is due to downstream targets of signal transduction pathways causing an integral
step of EMT, the loss of epithelial cadherin (E-cadherin) expression. These downstream targets
are zinc finger protein SNAI1 (Snail), zinc finger protein SNAI2 (Slug), zinc finger e-box
binding homeobox 1 (ZEB1, TCF8), zinc finger e-box binding homeobox 2 (ZEB2, SIP1), and
Twist-related protein 1 (Twist), that are known as EMT-associated transcription factors.
The second requirement for tumors to metastasize is the process of angiogenesis or
lymphangiogenesis, which is the formation of new blood vessels or lymphatic vessels,
respectively. Both processes allow for the primary tumor to connect to the blood stream or
lymphatic system, allowing for mesenchymal cells to run through to invade healthy tissues. Both

of these processes are initiated by the hypoxic conditions that the malignant tumor stimulates via
its own metabolism and proliferation [148].
Despite the general understanding of how metastasis occurs, there are several signal
transduction pathways involved in this process that are complicated. This paper aims to discuss
an up-to-date understanding of these signal transduction pathways, their cross-talks, and role in
metastasis, specifically in breast cancer metastasis. Figure 1 provides a visual of all of these
signal transduction pathways that are discussed in this paper. To download figure 1, please click
on the additional file above labeled as “Signal Transduction Pathways involved in EpithelialMesenchymal Transition.pdf” or click here: PDF image of Figure 1:

Figure 1. Shown above are the signal transduction pathways involved in Epithelial-Mesenchymal Transition
(EMT) , induced in breast cancer metastasis, by promoting an EMT-associated transcription factor (Slug (SNAI2),
SNAI1 (Snail), Zeb1 (TCF8), Zeb2, and Twist) caused by downstream targets. EMT is the biological process of
which epithelial cells lose their cell-cell adhesion and polarity, allowing for the cells to transition into a motile
mesenchymal state triggering metastasis. A hallmark of EMT is the repression of E-cadherin, which occurs when an
EMT-associated transcription factor is activated. EMT is involved in the initiation of metastasis, wound healing, and
development.
Second, angiogenesis or lymphangiogenesis must occur for metastasis to occur, which is the formation of
new blood vessels or lymphatic vessels. Cancer stem cells utilize the blood stream or lymphatic stream in order to
metastasize to different parts in the body. The process of angiogenesis is initiated by vascular endothelial growth
factor (VEGF), which binds to VEGFR on the interior of blood vessel walls. This causes endothelial cells to begin to
proliferate, to sprout out of the normal blood vessel to form a new blood vessel connected to the tumor. Activated
matrix metalloproteinase (MMP-3/9) aids in this process by degrading the proteins that keep the vessel walls solid.

WNT/β-catenin Signaling Pathway
The WNT signaling pathway plays a role in cell proliferation [2], cell polarity [4], cell fate
determination [5], and cell adhesion [3, 4]. WNT is a key signaling pathway that is used during
different steps of embryogenesis and adult tissue homeostasis. Therefore, it is an important
pathway to development [3]. Furthermore, this pathway is vital to the regulation of the levels of
β-catenin. β-catenin is important to EMT as it interacts with the E-cadherin/β-catenin complex
that plays an important role in maintaining epithelial cell’s integrity. This is due to β-catenin
decreasing the levels of E-cadherin by downstream targets of the WNT/β-catenin signaling
pathway [4]
Initiation of the Wnt signaling pathway begins with a Wnt-protein ligand binding to a
frizzled receptor sending a biological signal to activate the Dishevelled (Dsh) protein family.
Activated Dsh directly binds to glycogen synthase kinase 3 beta (GSK3β) to an inactive form,
causing functional β-catenin to accumulate in the cytosol and later translocate to the nucleus.
Normally, GSK3β phosphorylates and ubiquitinates β-catenin [6]. With the assistance of T-cell
factor / lymphoid enhancer factor (TCF/LEF), β-catenin activates the CD44 gene, Snail, and
Cyclo-Oxygenase 2 (COX-2) [7, 8, 9, 10]. CD44 activates the expression of an EMT-associated
transcription factor called ZEB1. ZEB1 also activates CD44 causing a positive feedback loop,
one that regulates the expression of ZEB1 through the repression of Epithelial Splicing
Regulatory Protein 1 (ESPR1) [11]. ZEB1 activates EMT through the downregulation of Ecadherin and upregulation of N-cadherin [12, 13]. ESRP1 regulates CD44 alternate splicing
during EMT, causing inhibition of another EMT-associated transcription factor, Snail. Therefore,
inhibition of ESRP1 is vital to EMT progression [14]. Activation of COX-2 leads to the
increased repression of E-cadherin by activation of Prostaglandin E2 receptor 2 and 4 (EP2, EP4)

[8, 15]. Activated EP2 and EP4, leads to the activation of adenylate cyclase, which increases the
levels of intracellular cyclic adenosine monophosphate (cAMP) [15, 16]. Intracellular cAMP
leads to the phosphorylation of GSK3β and phosphoinositide 3-kinases (PI3K) making a positive
feedback loop for the Wnt signaling pathway and the PI3K/AKT signaling pathway that will be
discussed later [17, 18].
Integrin Signaling Pathway
Integrins are members of the cell-extracellular matrix (ECM) and cell-adhesion
molecules that play important roles in regulating cell-cell adhesions; they are also involved in
making transmembrane connections to the cytoskeleton via activation of intracellular signaling
pathways. Furthermore, integrins play key roles in regulating development by controlling cell
migration, survival, proliferation, and differentiation [19, 20, 21]. Therefore, when integrins are
overexpressed in cancer it promotes signals that allow for cancer cells to survive, grow, and
differentiate [21]. Cancer cells also utilize the integrin pathway to dissemble the ECM to allow
for angiogenesis to occur [21]. The integrin signaling pathway begins with Integrin-Linked
Kinase (ILK) interacts with cytoplasmic domains of β1 and β3 integrins [22]. ILK’s downstream
targets negatively regulate GSK3β and positively regulate PI3K/AKT via phosphorylation [23].
ILK also directly activates the EMT-associated Transcription Factor Snail [24].
PI3K/AKT Signaling Pathway
The PI3K/AKT signaling pathway is important in regulating cell proliferation [25] and
survival [26, 27, 28, 29]. Breast cancer tumors utilize the PI3K/AKT pathway to aid in its own
survival, growth, and spread to other parts of the body, which are all downstream effects of this
pathway. Specifically, P13K/AKT leads to the activation of nuclear factor-kappa B (NF-κB), a

crucial protein complex that leads to several EMT-associated transcription factors, angiogenesis
and lymphangiogenesis, and activation of other pathways that breast cancer is involved in.
There are a variety of receptors that initiate this signaling transduction pathway such as:
human epidermal growth factor receptor 2 (HER 2) [30], receptor tyrosine kinase (RTK) [31],
insulin-like growth factor 1 (IGF-1) [32], transforming growth factor beta (TGF-β) [33], KISS1R
[34], and receptor activator of nuclear factor kappa-B (RANK) [35]. They all activate the
PI3K/AKT signaling pathway by phosphorylating PI3K [36, 37]. PI3K phosphorylates and
activates the serine/threonine protein kinase AKT (also known as Protein kinase B), causing a
series of downstream effects to occur such as the inhibition of GSK3β [38], activation of
endothelial NO synthase (eNOS) [39], phosphorylation of the complex of IKKα via Tyrosine
residue at 23 (T23) [40], and activation of mammalian Target of Rapamycin (mTOR) [41]. AKT
has also been shown to be activated by TWIST, an EMT-associated factor, in breast cancer cells
[42].
The regulation of the WNT/β-catenin pathway via activation of AKT, aids in the
induction of EMT in two different ways. First, AKT phosphorylates the serine at residue 552 in
β-catenin, increasing its transcriptional activity and aids in the movement of β-catenin from the
cytoplasm to the nucleus [43]. Second, AKT also phosphorylates serine at residue 9 in GSK3β,
which facilitates the ubiquitination and degradation of GSK3β, thus allowing for production of
β-catenin to increase [44, 45].
eNOS is responsible for the synthesis of nitric oxide (NO), which upregulates the WNT/
β-catenin by negatively regulating Dickkopf-related protein 1 (DKK1) gene expression, a gene
that regulates the WNT/β-catenin pathway [46]. Increased levels of NO in cancerous cells have
been shown to promote tumor angiogenesis, via activation of vascular endothelial growth factor

(VEGF). Therefore, promoting VEGF-induced neovascularization, increasing the tumor’s ability
to metastasize [47]. High levels of NO, in vivo, have also been shown to promote tumor
lymphangiogenesis in breast cancer cells, via activation of vascular endothelial growth factor c
(VEGF-C) [48]. The production of nitric oxide to promote VEGF, via hypoxia, is essential to
tumor metastasis, as it allows for channels to the blood and lymphatic stream to be created. NO
has also been shown to directly interact with COX-2, causing an increase in its enzyme activity
[49].
Phosphorylated AKT phosphorylates T23 in the inhibitor of nuclear factor kappa-B
kinase subunit alpha (IKKα) sub unit, which in turn, causes the inhibitor of nuclear factor kappaB kinase subunit beta (IκB) protein to be ubiquitinated. This leads to the activation of NF-κB via
phosphorylation [40]. Without this cascade of proteins activating each other through
phosphorylation, NF-κB is incapable of being activated for this pathway. The NF-κB signaling is
vital to the progression of EMT in breast cancer, as the inhibition of NF-κB, in vivo, has been
shown to block EMT from occurring [50]. This is due to the three EMT-transcription factors that
the NF-κB signaling pathway activates: Slug, TWIST1, and Zeb2 [51]. NF-κB may activate Slug
through activation of Myb proto-oncogene protein (C-myb), which has been shown to regulate
Slug in neuroblastoma cells. Since, C-myb is in high expressions in breast cancer, it may also
regulate Slug in breast cancer cells [52, 53, 54]. C-myb also positively regulates COX-2, a
protein used in the WNT/β-catenin pathway [55]. NF-κB regulates CD44, another protein used in
the WNT/β-catenin pathway, via activation of complement receptor type 1 (CR1) [56]. NF-κB
activation forms positive feedback loops with epidermal growth factor receptor (EGFR),
promoting each other, through a series of mechanisms discussed by Shostak & Chariot in [57].
An example of one feedback loop would be with the Heregulin-β1 (HRG-β1), a member of the

EGFR family, which upregulates VEGF-C, a lymphangiogenesis transcription factor, through the
activation of the NF-κB signaling pathway [58]. NF-κB may also act as a fibroblast growth
factor 2 (FGF-2) gene transcription factor, FGF-2 like VEGF, leads to angiogenesis, via
increased expression of matrix metalloproteinase-2/9 (MMP-2 and MMP-9) [59, 60, 61]. MMP2
and MMP-9 both are capable of breaking down the ECM, to allow for a new blood vessel to be
formed directly to the tumor [In addition, FGF-2 aids in the repression of E-cadherin while
inducing expression of vimentin, an EMT biomarker of a mesenchymal-derived cell [61]. NF-κB
regulates myc proto-oncogene protein (C-myc), which in turn activates microRNA-9 (miR-9), a
repressor of E-cadherin expression [62, 63]. C-myc regulates angiogenesis in tumors by
regulating an angiogenetic factor, VEGF [64, 65]. C-myc also crosstalks with the WNT/βcatenin pathway by being activated by β-catenin with TCF/LEF transcription factor and inhibits
adenomatosis polyposis coli (APC) on GSK3β [66]. NF-κB also regulates hypoxia-inducible
factor 1-alpha (HIF-1α) by binding directly to HIF-1α, initiating the hypoxic-related signaling
pathway that activates Twist and promotes angiogenesis [67, 68]. Furthermore, NF-κB
transcribes the SRY (Sex-Determining Region Y)-Box 9 Protein (SOX9) gene that cooperates
with Slug to cause EMT [69, 70]. Finally, NF-κB cross-talks with the Hedgehog signaling
pathway by upregulating the expression of the Sonic Hedgehog protein (SHH) [71].
There are two mTOR kinase complexes that AKT activates, mTORC1 and mTORC2 [72,
73]. AKT activates mTORC2 by phosphorylating an mTORC2 subunit known as SIN1. Once
SIN1 is phosphorylated, the mTORC2 signaling pathway is activated, leading to the
phosphorylation of AKT, forming a positive feedback loop. This interaction between mTORC2
and AKT leads to the full activation of AKT, allowing for EMT-associated transcription factors
to be upregulated [72]. Furthermore, mTORC2 aids in EMT progression by regulating MMP-9

expression through Snail, an EMT-transcription factor [74]. TGF-β induced mTORC2 has been
shown to be required for the progression of EMT in mammary epithelial cells, allowing the
cancerous cells to progress from an intermediate state of EMT to an advance mesenchymal,
invasive phenotype [74]. This is due to the vital proteins and kinases that mTORC2 regulates that
aid in EMT-associated cell migration and invasion, like MMP-9 and the actin cytoskeleton [74].
AKT activates mTORC1 by phosphorylation of IKKα, which then directly phosphorylates
mTORC1 [73]. On the other hand, mTORC1 has been shown to have a negative effect on EMT.
As the inhibition of mTORC1 in MCF10A human breast cell line with an active PLK3CA gene,
increased the cells invasiveness and activation of EMT [75]. The role of mTORC1 as an antiEMT kinase is in agreement with Mikaelian et. al., which showed that mTORC1 suppresses
EMT through the negative regulation of ZEB1/ZEB2 and microRNA-200b/c (miR-200b) and
miR-200c [76].

Ras/MEK Signaling Pathway
The mitogen-activated protein kinases (MAPK) cascade plays an important role in
proliferation, differentiation, development, and apoptosis [77]. Ras/MAPK signaling pathway is
important to the progression of breast cancer tumor as ligands like the epidermal growth factor
(EGF) is commonly overexpressed in cancer. EGF binds to EGFR, causing an activation of this
pathway, which increases cellular proliferation and inhibition of apoptosis [78]. Furthermore,
this pathway is important to EMT progression as it directly inhibits E-cadherin expression via
activation of several EMT-associated transcription factors.

This signal pathway begins by many ligands, like TGF-β, RTK, or EGF binding to its
receptor that sends a biological signal through the receptor to recruit the son of sevenless protein
(SOS) to Ras. With the assistance of SOS, Ras can exchange its guanosine diphosphate (GDP)
for a guanosine triphosphate (GTP), activating Ras [79]. Activated Ras initiates the Raf/
MAPK/ERK Kinase 1 (MEK1)/ extracellular signal–regulated kinases (ERK) signaling cascade,
known as the MAPK pathway, which is a series of kinases that control one another through
phosphorylation [80, 81, 82]. ERK has also been shown to be activated by TWIST in breast
cancer cells [42]. Phosphorylated ERK is necessary for EMT as it activates or regulates several
EMT-transcription factors like Slug, Snail, and ZEB1/2. Both ERK1/2 phosphorylate Slug [83].
Though only ERK2 has been found to upregulate Snail, which in turn activates ERK2, forming a
positive feedback loop, in breast cancer [84]. ERK2 also activates ZEB1/2, with the help of a
DEF motif [85].
RhoA/Rock
The Ras homolog gene family, member A (RhoA) signaling pathway is important in
EMT due to the pathway’s role in controlling the cell’s dynamic cytoskeletal organization and
cell motility [86]. TGF-β rapidly activates RhoA in epithelial cells, inducing the formation of
stress fibers that directly affect the actin cytoskeleton and mesenchymal characteristics in them
[87, 88]. This occurs because RhoA activates the Rho associated coiled-coil containing protein
kinase 1 (ROCK), which then phosphorylates LIM kinase-1 (LIMK), which then phosphorylates
cofilin [89, 90, 91]. Cofilin is responsible for tumor cell motility and invasion, as it directly
regulates actin polymerization and depolymerization during cell migration; Cofilin also is
capable of severing actin filaments [92, 93]. Therefore, high expressions of activated cofilin
promotes EMT by causing mammary epithelial cells to gain mesenchymal characteristics [93].

Smad Signaling Pathway
TGF-β regulates several cellular functions such as cell proliferation [94], adhesion [95],
migration [96, 97], cell-fate determination and differentiation [98], and apoptosis [99, 100]. The
Smad signaling pathway has been shown to be crucial to TGF-β-induced EMT as it promotes
two EMT-associated transcription factors, as well as crosstalk with other non-Smad pathways
that are important in EMT but are not described here. A review of these crosstalks, written by
Kunxin Luo is described in [101]. Though, the Smad and non-Smad pathways of TGF-β must
work together to contribute to the establishment of EMT [102].
SMADs are intracellular proteins essential for TGF-β, as their role is to transduce a signal
from the membrane into the nucleus and regulate gene expression by directly activating it [100].
The pathway begins by a TGF-β ligand binding to the TGF-β receptor, the TGF-β receptor then
phosphorylates SMAD family member 2 and 3 (SMAD 2, SMAD 3) [102]. Phosphorylated
SMAD2 and SMAD3 come together and recruit SMAD4 to form a trimer, which allows for this
complex to transport to the nucleus [10, 103, 104]. In the nucleus, this complex binds to DNAsequence-specific transcription factors to activate the transcription of Snail [105, 106, 107] and
Slug [10, 108, 109].
TAK1/JNK Signaling Pathway
TGF-β-activated kinase 1 (TAK1) signaling pathway has been shown to be crucial to the
regulation of genes that are involved in inflammation as it regulates expression levels of NF-κB
and activator protein 1 (AP-1). TAK1 has been shown to be required for TGF-β-induced c-Jun
N-terminal kinases (JNK) and NF-κB activation, in vivo [110]; the pathway is also essential for
TGF-β induce apoptosis, as overexpression of TAK1 caused cells to undergo apoptosis [111, 112,

113]. Furthermore, TAK1 signaling is required for TGF-β induced EMT as knockdown of TAK1
has been shown to inhibit TGF-β-mediated EMT [80, 114]. The activation of TGF-β causes the
polyubiquination of tumor necrosis factor-receptor associated factor-6 (TRAF6).
Polyubiquinated TRAF6 recruits and activates TAK1 [114, 115, 116]. Activated TAK1
ubiquinates and activates the IκB kinase (IKK), which increases the production of NF-κB by
activation IKKα as discussed before in this paper [40, 116]. In addition, activated TAK1
activates Mitogen-Activated Protein Kinase Kinase 3 (MKK3), 4 (MKK4), and 6 (MKK6).
MKK3 and MKK6 are responsible for the activation of p38. p38’s function in tumor metastasis
is still currently debated, with papers showing that p38 is a tumor suppressor while others
showing it positively contributes to tumorigenesis [119, 120, 121]. MKK4 is responsible for the
activation of JNK. JNK phosphorylates c-Jun which is part of AP-1 [117, 118]. AP-1 is a family
of proteins that are involved in inflammation as well as a central transcription factor associated
with cancer invasiveness and tumorigenesis [122]. For example, AP-1 regulates the transcription
of MMP3/9 expression, which promotes angiogenesis [123]. A molecule known as the epithelial
cell adhesion molecule (EpCAM) also works with AP-1 in cancer. Studies have shown that
EpCAM works with AP-1 to promote EMT through JNK phosphorylation [122, 124].The
expression of EpCAM has also been associated with increased breast cancer invasion in vitro and
in vivo [124]. Furthermore, EpCAM has been shown to be in a double negative feedback loop
with ERK2. EpCAM and ERK2 negatively regulate each other, though how this interaction
works to promote EMT is still not understood [125].
TNF-α Signaling Pathway
Tumor necrosis factor alpha (TNF-α) is a cytokine that is mainly utilized by macrophages
in response to inflammation [126]. In cancer, TNF-α is a key regulator of a tumor’s

microenvironment, while also contributing to tumor proliferation, invasion, survival, and
angiogenesis via downstream activation of NF-κB [126]. In breast cancer, increase TNF-α
expression level is associated with malignant breast cancer advancement as it aids in cell survival
and proliferation [127].
The TNF-α signaling pathway begins with a ligand binding to tumor necrosis factor
receptor type 1 (TNF-R1). This changes the receptor, leading to the dissociation of an inhibition
protein called silencer of death domain (SODD) allowing for the recruitment of tumor necrosis
factor receptor type 1 associated death domain protein (TRADD), tumor necrosis factor receptor
associated factor 2 (TRAF2), receptor interacting protein-1 (Rip1), and Fas-associated death
domain (FADD). to the receptor [128, 129]. The TRADD/TRAF2/Rip1/FADD complex allows
for the initiation of the NF-κB and JNK/Ap-1 pathway. TRADD recruits TRAF2, which recruits
the IKK complex. The IKK complex phosphorylates and ubiquitinates IκB, which as discussed
before increases the production of NF-κB. TRAF2 also recruits MAPK/ERK kinase kinase 1
(MEKK1), which activates MKK7, initiating the JNK/AP-1 cascade [128, 130].
Notch Signaling Pathway
The Notch signaling pathway is involved in cellular proliferation [131, 132], survival
[132, 133], apoptosis [132, 133], differentiation [131, 132], and angiogenesis [134]. Notch
signaling is important to cells as it maintains the balance of cell proliferation, differentiation, and
apoptosis. Therefore in cancer, when this balance is thrown off through upregulations in cell
proliferation, Notch is expressed [139]. In addition, Notch has recently been shown to be a key
factor in therapy resistance in estrogen receptor alpha (ER-α) positive breast cancer, as Notch
expression has been shown to increase in response to treatment [135, 136].

The pathway begins when ligands from the Delta- like members 1, 3, 4 (DLL1, DLL3, DLL4)
or Jagged 1 2 families (JAG1, JAG2) bind and cleave a Notch receptor [137]. This cleaving
causes the release of the intracellular domain of the Notch protein (NICD) from Notch through a
signaling cascade. NICD translocates to the nucleus and binds to the complex of C protein
binding factor 1/Suppressor of Hairless/Lag-1 (CSL) [137, 138, 139]. NICD then recruits
transcriptional activators to the CSL changing it from a transcriptional repressor to a
transcriptional activator complex. This active CSL complex increases the expression of a variety
of Notch target genes like NF-κB, AKT, mTOR, VEGF [137, 138, 139, 140]. Furthermore,
NICD directly upregulates the expression of Snail by binding to the Snail promoter [141,142].
Notch also indirectly regulates the expression of Snail by the activation of HIF-1α which can get
recruited to the lysyl oxidase (LOX) promoter resulting in the increased expression of LOX,
which stabilizes the Snail protein [142]. The NICD-CSL complex also upregulates the
expression of SLUG by directly regulating the SLUG promoter [143,144]. Acar and colleagues
discuss more about Notch in breast cancer in [145].
Hypoxia Signaling Pathway
Hypoxia, or oxygen deprivation in the body, is an important condition that plays a part in
proper embryonic development [146, 147], controlling tumor angiogenesis [148, 149], and tissue
growth [148, 149]. This signaling pathway helps restore oxygen homeostasis by inducing a
variety of factors [148]. As a tumor grows, it creates conditions of hypoxia that lead to the
activation of HIF-1α [150]. HIF-1α directly upregulates the expression of three EMTtranscription factors TWIST [151], Snail [152], ZEB1 [153], by binding to their promoters. HIF1α also promotes angiogenesis by increasing the expression of VEGF [154, 155].
Hedgehog/Sonic Signaling Pathway

The Hedgehog (Hh) signaling pathway plays important roles in embryonic development,
tissue self-renewal, mammary development, and carcinogenesis [150, 156, 157]. Sonic Hh
protein (SHH) has been observed to be expressed in high levels of triple negative breast cancer
with poor prognostic pathological features [158]. Furthermore, due to SHH role in the
maintenance of cancer stem cells, the Hh signaling pathway aids in the cancer stem cells survival
and expansion, by commencing and sustaining proliferation, invasion and metastasis [159,160].
Initiation of this signaling pathway begins with three Hh proteins, Desert (DHH), Indian
(IHH), and Sonic (SHH), that all act as a ligand to trigger a specific signal transduction pathway
[150, 157]. Specifically, SHH triggers the signaling transduction pathway that induces EMT in
breast cancer [161]. SHH binds to protein patched homolog 1(PTCH) stopping the inhibitory
effect of PTCH on the smoothened protein (SMO) [161]. Activated SMO translocates to the cilia
at the cell membrane and transactivates glioma-associated oncoproteins (GLI proteins: GLI1,
GLI2, GLI3) by sending a signal to the cilia to dissociate and release the GLI transcription factor
[150, 161, 162]. GLI1 and GLI2 proteins promotes EMT by increasing the expression of Snail
[163, 164], VEGFC [165], and VEGF [166, 167]. The activation of GLI1 is necessary for
Hedgehog-induced EMT, as knockdown of these oncoproteins leads to significantly reduced
proliferation and invasive capabilities in both estrogen receptor negative and triple negative
breast cancer [168]. Gli-1 also upregulates the expression of osteopontin, an oncogene that
promotes tumorigenesis and metastasis [169].
KISS1R Signaling Pathway
KISS1R signaling pathway has vital key functions in the regulation of placentation and
fetal development [233], insulin secretion, cardiovascular function [234], and kidney
development [235]. The KISS1 gene is known for its anti-metastatic effects in different types of

cancers such as pancreatic and lung cancer but in breast cancer, it is currently misunderstood
[170, 171]. Since, KISS1 has been linked with poor prognosis and breast tumor progression in
estrogen receptor positive breast cancer [172]. Though, estrogen receptor alpha (ERα) negatively
regulates KISS1. So, it may be that high expressions of KISS1 occur in breast tumor progression
as a result of either ERα losing its ability to negatively regulate KISS1 or KISS1 expression
overcoming the downregulation by ERα. [172].
Initiation of the pathway begins when a KISS1 gene encodes for peptide products known
as kisspeptin (KP) that serve as ligands that binds to the KISS1 receptor (KISS1R) [173]. This
interaction causes a biological signal to be sent through the receptor to transactivate EGFR [174],
activate Gαq/11 protein, and the Wiskott-Aldrich syndrome family 3 (WASF3). Activated
Gaq/11, leads to the direct upregulation of RhoA via the activation of a RhoA-specific guanine
nucleotide exchange factor known as p63RhoGEF [175, 176]. RhoA is important in tumor
metastasis as it regulates the actin cytoskeleton. Increased expression of WASF3 has an
inhibitory effect on the KISS1 gene that leads to the releasement of IκB, increasing NF-κB
expression. This leads to the upregulation of ZEB1, ZEB2, MMP-9 via NF-κB [177, 178]. The
loss of KISS1 expression, which is common in breast cancer metastases, then may be due to
WASF3 [179, 180]. In vitro, WASF3 has been shown to interact with HER2/3 to promote
invasion and metastasis in non-metastatic breast cancer cell lines [181]. Therefore, WASF3 may
be an oncogene of interest for potential treatment as it is directly involved in EMT and
angiogenesis through the upregulation of NF-κB.
To learn more about KISS/KISS1R in breast cancer, refer to Cvetković, Babwah, and
Bhattacharya’s review paper [182].

JAK/STAT3 Signaling Pathway
The Janus Kinase Family (JAK) / signal transducer and activator of transcription 3
(STAT3) pathway is involved in proliferation, differentiation, immunity, and apoptosis [183].
The signaling pathway is important to the proliferation of breast cancer cells as it regulates the
progression of the cell cycle and protects the cancer cells from apoptosis, [184]. Furthermore,
STAT3 aids in the tumors metabolism by activing genes that are involved in glycolysis, inducing
a hypoxic state [185]. This works by STAT3 directly activating HIF-1α; this interaction is
necessary for full activation of HIF-1α-regulated genes [186]. Also, STAT3 promotes
angiogenesis by directly binding to the VEGF promoter, increasing production of VEGF [187].
Initiation of the JAK/STAT3 begins with an Interleukin-6 (IL-6) binding to either
Interleukin-6 receptor (IL-6R) or an EGF binding to an EGFR [183]. IL-6R with IL-6 then
forms a heterotetrameric complex with glycoprotein 130 (gp130) which causes the activation of
the JAK1, JAK2, or TYK2 [188, 189]. The JAK family then phosphorylates gp130 that causes
the activation of STAT3, MAPK and PI3K/AKT [175, 176, 177]. STAT3 activation leads to the
regulation of cell transformation proliferation, survival, and motility [188, 189]. STAT3 aids in
EMT by activating both TWIST and Snail in ER-α-positive human breast cancer cells [191].
Though in node negative breast cancer, STAT3 expression is linked with better overall patient
prognosis and clinical outcome [192]. Furthermore, TWIST upregulates the production of IL-6,
forming a positive feedback loop that drives EMT [193]. Therefore, IL-6 is a receptor of interest
for treatment as it is capable of forming this positive feedback loop to continually increase the
production of TWIST, causing EMT [190]. STAT3 also directly binds to the WASF3 promoter,
an oncogene that is important in the KISS1/KISS1R signaling pathway [194].
RANK Signaling Pathway

The receptor activator of nuclear factor-kappa B ligand (RANKL) / receptor activator of
nuclear factor-kappa (RANK) signaling pathway is involved in the regulation of osteoclast
differentiation, activation, and proliferation and differentiation of mammary cells during
pregnancy [195]. RANKL expression is controlled by female sex hormones like progesterone or
estrogen [195], which are found commonly expressed in 70% of breast cancers [196]. Therefore,
this signaling pathway is hormone-driven to promote proliferation [196] and is commonly
overexpressed in breast cancer [197].
Initiation of the RANK/RANKL pathway begins when a Rank-L binds to RANK.
Activated RANK then activates an adapter protein known as TRAF6 [98]. Activated TRAF6
leads to the activation of PI3K/AKT/MTOR, MAPK (ERK, JNK) cascade, and induces the
transcription of vascular cell adhesion molecule 1 (VCAM1) or intercellular adhesion molecule 1
(ICAM1) by downstream targets like NF-κB [199, 200, 201]. VCAM1 and ICAM1 are both
involved in cell adhesion and motility, which is crucial to the progression of EMT, as VCAM1
upregulation has been shown to be directly correlated with advanced clinical breast cancer [202,
203]. Knockdown of VCAM1 by small interfering RNA (siRNA), inhibited cell growth in vitro
and in vivo and suppressed TGF-β or IL-6-stimulated cell migration, in vivo. Furthermore,
VCAM1 expression has been associated with several EMT related genes like E-cadherin, which
suggests its critical role in regulating EMT during breast tumor progression [202]. Though, the
mechanism of which VCAM1 regulates EMT is still poorly misunderstood and requires further
investigation.
In mammary tumor cell lines, RANK-induced EMT solely by the upregulation of Snail
and Twist via the activation of NF-κB. Tsubaki et. al. also found that they had no substantial
changes in levels of ERK1/2, AKT, Mtor,STAT3, and JNK after the addition of RANKL to the

mammary tumor cell line. They also found that inhibited NF-κB by Dimethyl Fumarate (DMF),
a NF-κB inhibitor, inhibited RANK-induced-EMT. DMF also decreased expression of Snail and
Twist, cell migration, and invasion, which proves that RANKL/RANK is dependent on the
activation of NF-κB to promote EMT [204].
RANKL may also have a role in the tumor microenvironment in breast cancer, as a
chemotactic factor that signals motile breast cancer cells to metastasize to bone [201, 205]. One
study which inhibited RANKL expression with Osteoprotegerin, significantly inhibited selective
metastasis to the bone, in an in vivo melanoma mice model [183]. This may be due to RANKL
role in osteoclastogenesis, which is the development of bone cells that break down bone tissue
[194, 205]. VCAM1 also is involved in osteoclastogenesis and may act as a chemoattract that
causes motile breast cancer cells to metastasize to the bone [206].
TIMP-1 Signaling Pathway
Tissue inhibitor of metalloproteinase-1 (TIMP-1) primarily is involved in the ECM,
which is important in development, cell-adhesion, Primarily, TIMP-1 directly regulates the ECM
by the inhibition of MMP-9, preventing angiogenesis [207]. In cancer, independent of MMP-9
inhibitory function, TIMP-1 regulates angiogenesis [208], cell survival [209], proliferation [210]
and apoptosis [209]. TIMP-1 expression is often linked with poor prognosis and increased in
advanced stage breast cancer [211]. There are other TIMPs like TIMP-3, that have been shown
to be in high expression in advanced stage breast cancers as well [211]. Though, TIMP-3 is often
silenced in cancer, leading to the development of advanced breast cancer [212].
First, TIMP-1 binds with a cell surface protein known as CD63 [213]. The CD63/TIMP1 complex directly promotes EMT, independent of its MMP-9-inhibitory function, by increasing

the expression of TWIST through the activation of cell survival cellular pathways in human
breast epithelial cells [214]. The specific pathways involved are still unclear but PI3K/AKT
seems like a likely pathway that CD63/TIMP-1 would activate if it is increasing cell survival and
TWIST.
TIMP-1 also crosstalks with the WNT/β-catenin pathway, as when TIMP-1 binds to
CD63 activated TIMP-1, it causes the decrease expression of let-7f, which in turn stabilizes the
levels of axin 2 [215] Axin 2 is a negative regulator of the WNT/β-catenin pathway as it leads to
the phosphorylation and degradation of β-catenin by interacting with GSK3β [215, 216].
OPN Signaling Pathway
Osteopontin (OPN) is a cytokine that is involved in the regulation of cell-matrix adhesion
[217], cell survival [217], bone remodeling [217], inflammation [218], and wound healing [218].
OPN is important in metastasis as it upregulates several EMT-associated transcription factors,
such as Twist, Zeb1, ZEB2, and Snail [219, 222]. OPN is essential to the initiation of EMT, as
inhibition of OPN in a xenograft breast cancer model, has been shown to decrease EMT [220]. In
ER positive and triple negative breast cancer, OPN is overexpressed; OPN overexpression has
been linked to aggressive breast cancer and poor prognosis [221].
OPN is a hypoxia-responsive gene that activates via HIF-1α. Activated OPN in hypoxic
and normal conditions also directly activates HIF-1α expression, suggesting a positive feedback
loop between OPN and HIF-1α that drives angiogenesis by the increase of VEGF expression
[223]. OPN also directly activates runt-related transcription factor 2 (Runx2) and in turn leads to
the activation of Snail in breast cancer [224, 225]. This interaction between Runx2 and Snail is
linked with poor prognosis and progression of breast cancer.

OPN phosphorylates nuclear factor inducing kinase (NIK) [226]. Phosphorylated NIK
activates the IKK signaling cascades to induce expression of NF-κB. This interaction leads to the
upregulation of MMP-9. NIK also is responsible for the activation of the MAPK pathway, which
leads to the phosphorylation of TWIST [227]. Then, Twist binds with the B lymphoma MoMLV insertion region 1 homolog (Bmi-1) promoter and cooperate with one another, to promote
EMT by the repression of E-cadherin [228].
Furthermore, OPN phosphorylates and activates the PI3K/AKT/NF-κB signaling cascade
via binding to a cell surface integrin known as alpha-v beta-3 (αvβ3) in breast cancer cells [229,
230]. OPN-NF-κB induced expression leads to the upregulation of ZEB1, ZEB2, and MMP-9
[228, 231]. Activated αvβ3 also activates MEKK1, which phosphorylates JNK, to promote the
expression of AP-1. AP-1 leads to the increase expression of MMP-9, an important matrix that
aids in angiogenesis [232].
Conclusion
EMT is very important to the progression of breast cancer, as without the process, cancer
is incapable of spreading to other parts of the body. EMT is regulated by several of these
interconnected signaling pathways that have been discussed here. There are various players
involved in the regulation of the process and with the various amounts of cross talk that occurs
throughout each of the pathways, mutations in one or two key genes can possibly give rise to
metastasis in cancer cells. Since, mutations in these genes can lead to overexpression of any of
these pathways that are all capable of decreasing E-cadherin expression directly or indirectly,
leading to EMT. Future studies should investigate further into the inhibition of WASF3 and IL-6
as possible treatments to prevent metastasis through their respected pathways. As well as
developing methods to prevent E-cadherin loss by directly targeting EMT-associated factors.
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